Kinnate Biopharma Inc. Quarterly Debt-to-equity in % from Q3 2022 to Q4 2023

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Kinnate Biopharma Inc. quarterly Debt-to-equity history and growth rate from Q3 2022 to Q4 2023.
  • Kinnate Biopharma Inc. Debt-to-equity for the quarter ending December 31, 2023 was 9.6 %, a 38.6% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q4 2023 9.6 +2.67 +38.6% Dec 31, 2023
Q3 2023 9.59 +3.95 +70% Sep 30, 2023
Q2 2023 8.83 Jun 30, 2023
Q1 2023 7.79 Mar 31, 2023
Q4 2022 6.93 Dec 31, 2022
Q3 2022 5.64 Sep 30, 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.